My view (opinion only) is that these results are highly unlikely to be negative and that should trigger a re-rating as much on the implications for the CHF trial as for the potential commercialization for LVAD. We are all gambling here but I think the share price still lags real value given the reduction in risk and increase in potential earnings we have seen over the past two months or so.
My view (opinion only) is that these results are highly unlikely...
-
- There are more pages in this discussion • 36 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.01 |
Change
0.028(2.81%) |
Mkt cap ! $1.153B | |||
| Open | High | Low | Value | Volume |
| 99.5¢ | $1.02 | 99.0¢ | $2.706M | 2.696M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 25 | 43057 | $1.01 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.01 | 182477 | 17 |
View Market Depth
| Last trade - 12.29pm 28/06/2024 (20 minute delay) ? |
| MSB (ASX) Chart |